Completion likely with self-administration of TB treatment

November 7, 2017

(HealthDay)—Most people complete treatment for latent tuberculosis (TB) without direct observation, according to a study published online Nov. 6 in the Annals of Internal Medicine.

Robert Belknap, M.D., from the University of Colorado Health Sciences Center in Denver, and colleagues compared treatment completion (11 or more doses within 16 weeks) and safety of once-weekly isoniazid and rifapentine by self-administration versus . A total of 1,002 adult patients with infection were recruited from outpatient tuberculosis clinics in the United States (77 percent), Spain, Hong Kong, and South Africa.

The researchers found that overall, treatment completion was 87.2 percent (95 percent interval, 83.1 to 90.5 percent) in the direct observation group , 74 percent (95 percent confidence interval, 68.9 to 78.6 percent) in the self-administration group, and 76.4 percent (95 percent confidence interval, 71.3 to 80.8 percent) in the self-administration-with-reminders group. In the United States, treatment completion was 85.4 percent (95 percent confidence interval, 80.4 to 89.4 percent), 77.9 percent (95 percent confidence interval, 72.7 to 82.6 percent), and 76.7 percent (95 percent confidence interval, 70.9 to 81.7 percent), respectively, and self-administered therapy without reminders was noninferior to direct observation. No other comparisons met noninferiority criteria.

"This self-administered regimen with monthly monitoring may be an acceptable strategy for treating latent TB infection in the United States and could be considered in countries with similar approaches to TB prevention when directly observed therapy is not feasible," conclude the authors.

Several authors disclosed ties to pharmaceutical companies, including Sanofi, which donated study drugs.

Explore further: PPI-gastric cancer link remains after H. pylori eradication

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

PPI-gastric cancer link remains after H. pylori eradication

November 2, 2017
(HealthDay)—Long-term proton pump inhibitor (PPI) use is associated with increased risk of gastric cancer (GC) even after Helicobacter pylori (HP) eradication therapy, according to a study published online Oct. 31 in Gut.

Extended-release naltrexone promising for opioid dependence

October 19, 2017
(HealthDay)—Extended-release naltrexone is noninferior to buprenorphine-naloxone for maintaining short-term abstinence from heroin and other illicit substances, according to a study published online Oct. 18 in JAMA Psychiatry.

Brain measures tied to atrial pressure in valvular heart Dz

November 7, 2017
(HealthDay)—For patients with chronic valvular heart disease, white matter hyperintensity (WMH) volume is associated with mean right atrial (RA) pressure, according to a study published online Nov. 6 in JAMA Neurology.

CYP2C19-genotype guided antiplatelet tx may be beneficial

November 3, 2017
(HealthDay)—Patients with a CYP2C19 loss-of-function allele have increased risk of major adverse cardiovascular events (MACE) with clopidogrel versus alternative antiplatelet therapy after percutaneous coronary intervention ...

Probiotics linked to weight loss in obese, overweight

October 29, 2017
(HealthDay)—Short-term probiotics are associated with reductions in body weight, body mass index (BMI), and fat percentage in overweight or obese subjects, according to research published online Oct. 18 in Obesity Reviews.

Occult cancer found in ~5 percent with unprovoked VTE

August 23, 2017
(HealthDay)—About one in 20 patients with unprovoked venous thromboembolism (VTE) have occult cancer detected within one year, according to a review published online Aug. 22 in the Annals of Internal Medicine.

Recommended for you

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

A new class of drug to treat herpes simplex virus-1 infection

February 14, 2018
For patients with the herpes simplex-1 virus (HSV-1), there are just a handful of drugs available to treat the painful condition that can affect the eyes, mouth and genitals.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.